Physician profile
Omer Tarar
NPI 1891161162
$4,542.75
in general payments reported to CMS, 2019-2025
36 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $101 · 2021: $2,360 · 2022: $700 · 2023: $338 · 2024: $68.92 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.30 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.44 | 2019-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $399.68 | 2021-2022 | |
| Dexcom, INC. | $334.96 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $253.17 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $243.72 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.70 | 2021-2023 | Jardiance |
| Abbvie INC. | $234.66 | 2020-2025 | Ubrelvy |
| Medtronic Minimed, INC. | $195.88 | 2019 | |
| Insulet Corporation | $191.10 | 2021-2025 | Omnipod |
| Amarin Pharma, INC. | $185.55 | 2021-2022 | |
| Esperion Therapeutics, INC. | $153.41 | 2021 | |
| Chiesi USA, INC. | $146.96 | 2025 | Mycapssa |
| Lilly USA, LLC | $141.09 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $140.19 | 2025 | Xacduro |
| Mannkind Corporation | $132.99 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $122.16 | 2021-2022 | |
| Penumbra, INC. | $115.00 | 2023 | Indigo System |
| Eisai INC. | $91.73 | 2021-2022 | |
| Amgen INC. | $88.79 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $84.88 | 2023 | Opsumit, Uptravi |
| Recordati_rare_diseases_inc. | $72.43 | 2021 | |
| Beta Bionics, INC. | $65.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nestle Healthcare Nutrition INC. | $64.91 | 2020-2021 | |
| Radius Health, INC. | $62.14 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $53.99 | 2021-2022 | |
| Corcept Therapeutics | $53.95 | 2021-2025 | Korlym |
| Clarus Therapeutics INC. | $38.29 | 2021 | |
| Amneal Pharmaceuticals LLC | $28.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.31 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.08 | 2022 | |
| Antares Pharma, INC. | $21.16 | 2021 | |
| Pfizer INC. | $16.33 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.75 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.66 | 2022 | |
| Ibsa Pharma INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Tarar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.